{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:56:15Z","timestamp":1780606575822,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Ministry of Health Labour and Welfare","award":["H30-Intractable diseases (general)-015"],"award-info":[{"award-number":["H30-Intractable diseases (general)-015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12185-021-03212-9","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:45:42Z","timestamp":1630709142000},"page":"11-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1854-4543","authenticated-orcid":false,"given":"Masahiro","family":"Ieko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiyoshi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kiyohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinri","family":"Miyazima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Maeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Shimosegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitada","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"3212_CR1","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","volume":"109","author":"PW Collins","year":"2007","unstructured":"Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. UK Haemophilia Centre Doctors\u2019 Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation. Blood. 2007;109:1870\u20137.","journal-title":"Blood"},{"key":"3212_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","volume":"120","author":"F Baudo","year":"2012","unstructured":"Baudo F, Collins P, Huth-Kuhne A, Levesque H, Marco P, Nemes L, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012;120:39\u201346.","journal-title":"Blood"},{"key":"3212_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/9780470757260.ch16","volume-title":"Inhibitors in patients with haemophilia","author":"CM Kessler","year":"2002","unstructured":"Kessler CM, Nemers L. Acquired inhibitors to factor VIII. In: Rodringuez EC, Lee CA, editors. Inhibitors in patients with haemophilia. Oxford: Blackwell Publishing; 2002. p. 98\u2013112."},{"key":"3212_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0950-3536(98)80049-8","volume":"11","author":"CR Hay","year":"1998","unstructured":"Hay CR. Acquired haemophilia. Baillieres Clin Haemotol. 1998;11:287\u2013303.","journal-title":"Baillieres Clin Haemotol"},{"key":"3212_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1756-0500-3-161","volume":"3","author":"P Collins","year":"2010","unstructured":"Collins P, Baudo F, Huth-K\u00fchne A, Ingerslev J, Kessler CM, Castellano MEM, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010;3:161.","journal-title":"BMC Res Notes"},{"key":"3212_CR6","first-page":"498","volume":"13","author":"M Franchini","year":"2015","unstructured":"Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, et al. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus. 2015;13:498\u2013513.","journal-title":"Blood Transfus"},{"key":"3212_CR7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2141.2000.02327.x","volume":"111","author":"CR Hay","year":"2000","unstructured":"Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors\u2019 Organization (UKHCDO). Br J Haematol. 2000;111:78\u201390.","journal-title":"Br J Haematol"},{"key":"3212_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/hae.12138","volume":"19","author":"JY Borg","year":"2013","unstructured":"Borg JY, Guillet B, Le Cam-Duchez V, Goudemand J, L\u00e9vesque H, SACHA Study Group. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry. Haemophilia. 2013;19:564\u201370.","journal-title":"Haemophilia"},{"key":"3212_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2491\/jjsth.19.140","volume":"19","author":"I Tanaka","year":"2008","unstructured":"Tanaka I, Amano K, Taki M, Oka T, Sakai M, Shirahata A, et al. A 3-year consecutive survey on current status of acquired inhibitors against coagulation factors in Japan\u2500analysis of prognostic factors. J Jpn Soc Thromb Hemost. 2008;19:140\u201353.","journal-title":"J Jpn Soc Thromb Hemost"},{"key":"3212_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/bjh.12091","volume":"160","author":"PW Collins","year":"2013","unstructured":"Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160:153\u201370.","journal-title":"Br J Haematol"},{"key":"3212_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1055\/s-0038-1653759","volume":"73","author":"B Verbruggen","year":"1995","unstructured":"Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247\u201351.","journal-title":"Thromb Haemost"},{"key":"3212_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1365-2516.2008.01924.x","volume":"16","author":"B Verbruggen","year":"2010","unstructured":"Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia. 2010;16:20\u20134.","journal-title":"Haemophilia"},{"key":"3212_CR13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2516.2009.02173.x","volume":"16","author":"EJ Favaloro","year":"2010","unstructured":"Favaloro EJ, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K, et al. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. Haemophilia. 2010;16:662\u201370.","journal-title":"Haemophilia"},{"key":"3212_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12185-019-02674-2","volume":"110","author":"M Ieko","year":"2019","unstructured":"Ieko M, Yoshida M, Naito S, Ohmura K, Takahashi N. Lupus anticoagulant-hypoprothrombinemia syndrome and similar diseases: experiences at a single center in Japan. Int J Hematol. 2019;110:197\u2013204.","journal-title":"Int J Hematol"},{"key":"3212_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2491\/jjsth.29.251","volume":"29","author":"A Ichinose","year":"2018","unstructured":"Ichinose A. The present condition of and clinical guidance for autoimmune coagulation factor deficiencies in Japan. J Jpn Soc Thromb Hemost. 2018;29:251\u201361.","journal-title":"J Jpn Soc Thromb Hemost"},{"key":"3212_CR16","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/j.1365-2516.2008.01785.x","volume":"14","author":"JN Huang","year":"2008","unstructured":"Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia. 2008;14:1164\u20139.","journal-title":"Haemophilia"},{"key":"3212_CR17","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.26420\/annhematoloncol.2017.1173","volume":"4","author":"F Boland","year":"2017","unstructured":"Boland F, Shreenivas AV. Acquired factor V inhibitors: a review of literature. Ann Hematol Oncol. 2017;4:1168.","journal-title":"Ann Hematol Oncol"},{"key":"3212_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2169\/internalmedicine.9150-17","volume":"57","author":"K Nakata","year":"2018","unstructured":"Nakata K, Ueda S, Matsunaga H, Mima F, Ueda H, Yoshioka A, et al. High titer of acquired factor V Inhibitor presenting with a pseudo-deficiency of multiple coagulation factors. Intern Med. 2018;57:393\u20137.","journal-title":"Intern Med"},{"key":"3212_CR19","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00277-012-1485-3","volume":"91","author":"T Higuchi","year":"2012","unstructured":"Higuchi T, Okamoto T, Kou T, Takeuchi T, Koyamada R, Okada S. Deep vein thrombosis associated with factor V inhibitor followed by immune thrombocytopenia. Ann Hematol. 2012;91:1831\u20132.","journal-title":"Ann Hematol"},{"key":"3212_CR20","first-page":"206","volume":"78","author":"I Ghachem","year":"2020","unstructured":"Ghachem I, El Borgi W, Fekih Salem S, Ben Lakhal F, Chelbi A, Ghiriani I, et al. Haemodialysis Tunisian patient with acquired factor V inhibitor associated to arteriovenous shunt thrombosis. Ann Biol Clin (Paris). 2020;78:206\u20139.","journal-title":"Ann Biol Clin (Paris)"},{"key":"3212_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s12185-020-02983-x","volume":"112","author":"M Ieko","year":"2020","unstructured":"Ieko M, Komiyama Y, Yamazaki S, Katagiri H, Shimazu C, Naito S, et al. Expert consensus regarding standardization of sample preparation for clotting time assays. Int J Hematol. 2020;112:614\u201320.","journal-title":"Int J Hematol"},{"key":"3212_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/jth.13304","volume":"14","author":"S Werwitzke","year":"2016","unstructured":"Werwitzke S, Geisen U, Nowak-G\u00f6ttl U, Eichler H, Stephan B, Scholz U, et al. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01\/2010 study. J Thromb Haemost. 2016;14:940\u20137.","journal-title":"J Thromb Haemost"},{"key":"3212_CR23","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1055\/s-0039-1692427","volume":"119","author":"J M\u00fcller","year":"2019","unstructured":"M\u00fcller J, Pekrul I, P\u00f6tzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost. 2019;119:1384\u201393.","journal-title":"Thromb Haemost"},{"key":"3212_CR24","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/bloodadvances.2017011536","volume":"1","author":"M Rota","year":"2017","unstructured":"Rota M, Cortesi PA, Crea R, Gringeri A, Mantovani LG. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv. 2017;1:2637\u201342.","journal-title":"Blood Adv"},{"key":"3212_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","volume":"125","author":"CJ Hofbauer","year":"2015","unstructured":"Hofbauer CJ, Whelan SF, Hirschler M, Allacher P, Horling FM, Lawo JP, et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and non-neutralizing antibodies in humans. Blood. 2015;125:1180\u20138.","journal-title":"Blood"},{"key":"3212_CR26","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1182\/blood.V89.10.3663","volume":"89","author":"R Prescott","year":"1997","unstructured":"Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood. 1997;89:3663\u201371.","journal-title":"Blood"},{"key":"3212_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0049-3848(00)00418-7","volume":"101","author":"DH Scandella","year":"2001","unstructured":"Scandella DH, Nakai H, Felch M, Mondorf W, Scharrer I, Hoyer LW, et al. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Thromb Res. 2001;101:377\u201385.","journal-title":"Thromb Res"},{"key":"3212_CR28","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1538-7836.2004.00802.x","volume":"2","author":"P Lollar","year":"2004","unstructured":"Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost. 2004;2:1082\u201395.","journal-title":"J Thromb Haemost"},{"key":"3212_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood-2016-11-751347","volume":"130","author":"J Kahle","year":"2017","unstructured":"Kahle J, Orlowski A, Stichel D, Healey JF, Parker ET, Jacquemin M, et al. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. Blood. 2017;130:808\u201316.","journal-title":"Blood"},{"key":"3212_CR30","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2016-02-701805","volume":"128","author":"G Batsuli","year":"2016","unstructured":"Batsuli G, Deng W, Healey JF, Parker ET, Baldwin WH, Cox C, et al. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors. Blood. 2016;128:2055\u201367.","journal-title":"Blood"},{"key":"3212_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/ejh.13249","volume":"103","author":"C Hoffmann","year":"2019","unstructured":"Hoffmann C, Amiral J, Rezig S, Kerspern H, Jantzem H, Robin S, Collins A, Mornet C, Mingant F, Pan Petesch B, Ianotto JC, Lippert E, Galinat H. A very potent factor V inhibitor interferes with the levels of all coagulation factors and causes a fatal hemorrhagic syndrome. Eur J Haematol. 2019;103:137\u20139.","journal-title":"Eur J Haematol"},{"key":"3212_CR32","doi-asserted-by":"crossref","first-page":"bcr2013010018","DOI":"10.1136\/bcr-2013-010018","volume":"2013","author":"A Khalafallah","year":"2013","unstructured":"Khalafallah A, Grabek J, Hayes R, Mohamed M. Bleeding associated with acquired factor V inhibitor in a patient on warfarin treated successfully with prednisolone. BMJ Case Rep. 2013;2013:bcr2013010018.","journal-title":"BMJ Case Rep"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03212-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03212-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03212-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T19:27:59Z","timestamp":1725737279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03212-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3212"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03212-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have conflicts related to financial or personal relationships that may be considered as potential competing interests to declare in regard to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}